|Genfit SA -- USA Stock|| |
USD 26.77 0.56 2.05%
Member of the Supervisory Board, Representative of Biotech Avenir
Ms. Florence Sejourne has served as Member of the Supervisory Board, Representative of Biotech Avenir at Genfit SA since June 14, 2010. Prior to this, she was Member of the Management Board and Director of Operations of the Company from September 15, 1999 to May 28, 2008. She was Member of the Management Committee of Biotech Avenir and Cadialpha and Member of the Management Board of IT.Omics. She started her professional career in the immunology research department of Centre de Recherche Roussel Uclaf in Romainville, France. Between 1994 and 1996, she worked within the pharmaceutical department of the University of Illinois, Chicago. In 1997, she joined Eurasante as Head of the Biopharmaceutical department. She has a Masters degree in Pharmaceutical Studies from the University of Illinois and a degree in Biotechnology from Ecole des Mines de Paris.
Executive Since 2010
33 3 20 16 40 00 http://www.genfit.com
The company has return on total asset (ROA)
of (21.4) %
which means that it has lost $21.4 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE)
of (41.34) %
meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 10.12 M in total debt with debt to equity ratio (D/E) of 7.0 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Genfit SA has Current Ratio of 7.18 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.
Genfit SA, a biopharmaceutical company, develops therapeutic and diagnostic solutions to address high unmet patient needs in metabolic and inflammatory diseases with a focus on the liver and gastroenterology worldwide. Genfit SA (GNFTF) is traded on OTC Market in USA. It is located in , Avenue Eug?ne Avin?eLoos, and employs 108 people.